Market capitalization | $142.86m |
Enterprise Value | $281.96m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 0.92 |
P/S ratio (TTM) P/S ratio | 0.46 |
P/B ratio (TTM) P/B ratio | negative |
Revenue growth (TTM) Revenue growth | 69.37% |
Revenue (TTM) Revenue | $308.13m |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
8 Analysts have issued a Coherus BioSciences, Inc. forecast:
8 Analysts have issued a Coherus BioSciences, Inc. forecast:
Jun '24 |
+/-
%
|
||
Revenue | 308 308 |
69%
69%
|
|
Gross Profit | 123 123 |
39%
39%
|
|
EBITDA | -151 -151 |
34%
34%
|
EBIT (Operating Income) EBIT | -157 -157 |
33%
33%
|
Net Profit | -29 -29 |
89%
89%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Coherus BioSciences, Inc. is a commercial-stage clinical biologics platform company, which engages in the development and commercialization of biosimilar therapeutics. Its clinical products include pegfilgrastim biosimilar, adalimumab biosimilar, etanercept biosimilar, ranibizumab biosimilar, and aflibercept biosimilar. The company was founded by Dennis M. Lanfear, Stuart E. Builder, Dr. Alan Herman, Doug Farrar and Steve Glover in September 2010 and is headquartered in Redwood City, CA.
Head office | United States |
CEO | Denny Lanfear |
Employees | 306 |
Founded | 2010 |
Website | www.coherus.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.